Drug intelligence / Profile preview

MDI-26478

Development stage: Unknown
Lead developer: Cardiff University Medicines Discovery Institute
Modality: Small Molecules

Overview

**MDI-26478** is a small molecule positive allosteric modulator of the AMPA receptor, developed by Cardiff University’s Medicines Discovery Institute (MDI) to address cognitive impairment in schizophrenia. The AMPA receptor plays a key role in brain health and synaptic plasticity, and enhancing its activity with MDI-26478 aims to improve cognitive performance. It has completed the first stage of a phase 1 clinical trial, demonstrating safety across all doses tested, with ongoing studies focusing on efficacy, neuroimaging, and neurophysiological effects.[1][2][3][4][5]

Targets

AMPAR (AMPA receptor)

Beyond the preview

Go deeper on MDI-26478.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MDI-26478.

Explore the full profile